Publikationen in Zusammenarbeit mit Forschern von Hospital Universitari Germans Trias i Pujol (21)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  2. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

  3. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

    The Lancet Haematology, Vol. 11, Núm. 9, pp. e659-e670

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

    Blood, Vol. 139, Núm. 10, pp. 1588-1592

  3. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

    International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392

  4. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2021

  1. Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: A randomized phase 3 study

    Blood Advances, Vol. 5, Núm. 17, pp. 3354-3361

  2. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

    Cancer Medicine, Vol. 10, Núm. 4, pp. 1314-1326

2020

  1. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

    Experimental Hematology and Oncology

  2. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)

    British Journal of Haematology, Vol. 190, Núm. 6, pp. 854-863

2017

  1. CT-P10 versus reference rituximab in combination with CVP in advanced-stage follicular lymphoma: Phase 3, double-blind, randomized trial

    Annals of Oncology, Vol. 28, pp. x94

  2. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

    The Lancet Haematology, Vol. 4, Núm. 8, pp. e362-e373

  3. Linfomas con reordenamiento de MYC distintos del linfoma de Burkitt: comparación entre R-CHOP y la inmunoquimioterapia tipo Burkitt

    Medicina Clinica, Vol. 149, Núm. 8, pp. 339-342

2015

  1. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale

    Journal of Geriatric Oncology, Vol. 6, Núm. 5, pp. 353-361

2013

  1. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: Final results of a phase 2 study (Burkimab)

    Cancer, Vol. 119, Núm. 9, pp. 1660-1668

2012

  1. Chronic lymphocytic leukaemia with 17p deletion: A retrospective analysis of prognostic factors and therapy results

    British Journal of Haematology, Vol. 157, Núm. 1, pp. 67-74

2002

  1. Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease

    AIDS, Vol. 16, Núm. 14, pp. 1973-1976

2001

  1. Estudio de los componentes moleculares de la hemoglobina mediante electrospray acoplado a espectrometria de masas. Aplicación a la detección del aminoácido responsable de la mutación en la hemoglobina S

    Quimica Clinica, Vol. 20, Núm. 2, pp. 57-63

2000

  1. Dolor abdominal y diarrea en un varón de 33 años

    Medicina Clinica, Vol. 115, Núm. 7, pp. 271-277